On September 21, Yifan Pharmaceutical and South Korea's Boryeong Pharmaceutical announced that they had reached a cooperation. Yifan Pharmaceutical obtained general agency rights for Taisoti® in China and is fully responsible for the marketing, channel distribution and commercial operation of this product within China. The original research manufacturer of Tesco is Sanofi. At the end of September 2025, South Korea's Boryeong Pharmaceutical officially disclosed that it had obtained full global business interests from Tesco. Taizoti is an anti-microtubule cytotoxic antineoplastic drug that is widely used in the treatment of solid tumors such as breast cancer, non-small cell lung cancer, prostate cancer, stomach cancer, and head and neck cancer.

On September 21, Yifan Pharmaceutical and South Korea's Boryeong Pharmaceutical announced that they had reached a cooperation. Yifan Pharmaceutical obtained general agency rights for Taisoti® in China and is fully responsible for the marketing, channel distribution and commercial operation of this product within China. The original research manufacturer of Tesco is Sanofi. At the end of September 2025, South Korea's Boryeong Pharmaceutical officially disclosed that it had obtained full global business interests from Tesco. Taizoti is an anti-microtubule cytotoxic antineoplastic drug that is widely used in the treatment of solid tumors such as breast cancer, non-small cell lung cancer, prostate cancer, stomach cancer, and head and neck cancer.